USA flag logo/image

An Official Website of the United States Government

Novel Neuroprotective/Restorative Therapy for Ischemic Stroke

Award Information

Department of Health and Human Services
Award ID:
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
Solicitation Year:
Solicitation Topic Code:
Solicitation Number:
Small Business Information
51 Charles Lindbergh Blvd Uniondale, NY -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Phase 2
Fiscal Year: 2009
Title: Novel Neuroprotective/Restorative Therapy for Ischemic Stroke
Agency: HHS
Contract: 2R44NS045373-02A2
Award Amount: $2,297,251.00


DESCRIPTION (provided by applicant): Ischemic Stroke continues to be a major cause of morbidity and mortality in the United States. Currently approved thrombolytic therapy suffers for a narrow therapeutic window and clearly other therapeutic strategies are needed, such as neuroprotective or restorative agents. Unfortunately the quest for a therapeutic remains beset by a history of failed clinical trials involving promising neuroprotective candidates. Instead of targeting a single pathway in the cascade lead ing to ischemic neuronal damage, treatment with multifunctional compounds or supplements of endogenous multirole factors might be better choices for preventing ischemic brain injury. One of the most exciting areas of research for treatment of cerebral isch emia is the use of angiogenic growth factors, agents that exert direct neuroprotective effects and augment blood flow to the ischemic region. Scatter factor/hepatocyte growth factor (SF/HGF) neurotrophic, reduces cerebral infarct size, augments cerebral bl ood flow and promotes neuritogenesis and synaptogenesis, the growth of mature, functional neurons specifically in the per-infarct region or penumbra. These cellular effects lead to improved memory and learning in long term rodent studies even when HGF is g iven 7 days after the start of the ischemic insult. While administration of SF/HGF as gene or protein therapy has potential for the treatment of ischemic stroke, the therapeutic feasibility of this approach is limited by the presence of the blood-brain-bar rier, and other issues such as immune and inflammatory responses evoked by adenovirus proteins, inherent instability of proteins in solution, their limited tissue half-life and cost-prohibitive production. We have identified Refanalin, an organic small-mol ecule SF/HGF mimetic that crosses the blood brain barrier , exerts neuroprotective effects (even when administered in a delayed setting) and augments psot ischemic blood flow in rat models of temporary and permanent mid-cerebral artery occlusion, tMCAO and pMCAO, respectively. This research effort is a collaborative agreement between Angion Biomedica Corp. and Dr. David Warner of Duke University to rigorously and independently test the dose, therapeutic window, and therapeutic duration of Refanalin in short and long term rat models of tMCAO and pMCAO, and addressing gender differences and activity in aged animals. This aggressive research plan will meet most of the recommendations of the Stroke Therapy Academic Industry Roundtable (STAIR) of 1999, which stil l remains the standard for preclinical drug development for stroke neuroprotective and restorative drugs. With the anticipated, positive outcome for Refanalin in our studies, Angion will be prepared to complete preclinical development, including testing Re fanalin in non-human primate models before approaching the FDA with an IND package. PUBLIC HEALTH RELEVANCE: Ischemic stroke is a major cause of death in the United States. Unfortunately attempts at finding new neuroprotective therapies have failed miserab ly in clinical trials. Refanalin, a small molecular weight mimetic of HGF has been shown to protect brain cells in animal models and may prove to be a novel therapy to treat ischemic stroke.

Principal Investigator:

David E. Smith

Business Contact:

Itxhak D. Goldberg
Small Business Information at Submission:


EIN/Tax ID: 113430072
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No